Morning vs. evening: can timing boost melanoma treatment?
NCT ID NCT07155317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly assigned to morning, afternoon, or evening treatment. The goal is to see if timing can improve how long the cancer stays under control and reduce side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ACRAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Emory Saint Joseph's Hospital
NOT_YET_RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Email: •••••@•••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a Gut-Focused drug revive immunotherapy for tough melanomas?
- Blood test aims to spot hidden cancer cells in 9 tumor types
- Wheat germ supplement studied for immune boost in advanced cancer
- Can morning light boost melanoma treatment? new trial tests simple iPad therapy
- Engineered immune cells take on Hard-to-Treat melanoma